Genentech on Wednesday rejected an unsolicited $43.7bn takeover bid from its majority owner Roche but suggested it would consider a higher offer.

The US group, one of the world’s largest biotechnology companies, said Roche’s $89 per share bid “substantially undervalues” its business.